164 related articles for article (PubMed ID: 19522699)
1. Recent advances in epitope design for immunotherapy of cancer.
Chiarella P; Massi E; De Robertis M; Fazio VM; Signori E
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):227-40. PubMed ID: 19522699
[TBL] [Abstract][Full Text] [Related]
2. Synthetic peptides as cancer vaccines.
Sundaram R; Dakappagari NK; Kaumaya PT
Biopolymers; 2002; 66(3):200-16. PubMed ID: 12385038
[TBL] [Abstract][Full Text] [Related]
3. Melanoma vaccines: achievements and perspectives.
Brichard VG; Gérard C
Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
[TBL] [Abstract][Full Text] [Related]
4. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in design of immunogenic and effective naked DNA vaccines against cancer.
Fioretti D; Iurescia S; Rinaldi M
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):66-82. PubMed ID: 23444943
[TBL] [Abstract][Full Text] [Related]
6. Are mimotope vaccines a good alternative to monoclonal antibodies?
Pourjafar M; Samadi P; Khoshinani HM; Saidijam M
Immunotherapy; 2019 Jun; 11(9):795-800. PubMed ID: 31094256
[TBL] [Abstract][Full Text] [Related]
7. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
8. Poxvirus-based vaccines for cancer immunotherapy: new insights from combined cytokines/co-stimulatory molecules delivery and "uncommon" strains.
Izzi V; Buler M; Masuelli L; Giganti MG; Modesti A; Bei R
Anticancer Agents Med Chem; 2014 Feb; 14(2):183-9. PubMed ID: 24237219
[TBL] [Abstract][Full Text] [Related]
9. Peptide-based anticancer vaccines: recent advances and future perspectives.
Mocellin S; Pilati P; Nitti D
Curr Med Chem; 2009; 16(36):4779-96. PubMed ID: 19929787
[TBL] [Abstract][Full Text] [Related]
10. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker].
Hazama S; Maeda K; Oka M
Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic cancer vaccines: at midway between immunology and pharmacology.
Lage A; Perez R; Fernandez LE
Curr Cancer Drug Targets; 2005 Dec; 5(8):611-27. PubMed ID: 16375666
[TBL] [Abstract][Full Text] [Related]
12. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery.
Sette A; Fikes J
Curr Opin Immunol; 2003 Aug; 15(4):461-70. PubMed ID: 12900280
[TBL] [Abstract][Full Text] [Related]
13. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
14. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
[TBL] [Abstract][Full Text] [Related]
15. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
16. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome.
Voskens CJ; Strome SE; Sewell DA
Curr Mol Med; 2009 Aug; 9(6):683-93. PubMed ID: 19689295
[TBL] [Abstract][Full Text] [Related]
17. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Sahin U; Derhovanessian E; Miller M; Kloke BP; Simon P; Löwer M; Bukur V; Tadmor AD; Luxemburger U; Schrörs B; Omokoko T; Vormehr M; Albrecht C; Paruzynski A; Kuhn AN; Buck J; Heesch S; Schreeb KH; Müller F; Ortseifer I; Vogler I; Godehardt E; Attig S; Rae R; Breitkreuz A; Tolliver C; Suchan M; Martic G; Hohberger A; Sorn P; Diekmann J; Ciesla J; Waksmann O; Brück AK; Witt M; Zillgen M; Rothermel A; Kasemann B; Langer D; Bolte S; Diken M; Kreiter S; Nemecek R; Gebhardt C; Grabbe S; Höller C; Utikal J; Huber C; Loquai C; Türeci Ö
Nature; 2017 Jul; 547(7662):222-226. PubMed ID: 28678784
[TBL] [Abstract][Full Text] [Related]
18. Cancer testis antigens--their importance in immunotherapy and in the early detection of cancer.
Suri A
Expert Opin Biol Ther; 2006 Apr; 6(4):379-89. PubMed ID: 16548764
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
20. T-cell-directed cancer vaccines: the melanoma model.
Wang E; Phan GQ; Marincola FM
Expert Opin Biol Ther; 2001 Mar; 1(2):277-90. PubMed ID: 11727535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
